Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098205 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL345737 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL345736 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL617316 | 1.00 | RIPK1 (0.34) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL2591304 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL13860171 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL4390283 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL2942462 | 0.89 | RIPK1 (0.33) | RIPK1LMNA | |
| SCHEMBL4388287 | 0.89 | HSD17B10 (0.38) | RIPK1LMNADPP4CYP2C19HSD17B10 | |
| SCHEMBL23527330 | 0.87 | RIPK1 (0.33) | RIPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | XINTHERA, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-20060167016-A1 | 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1525202-B1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| EP-1525202-A1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-6846835-B2 | Treating chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory tract obstruction, fibroid lung, pulmonary emphysema or rhinitis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-01-25 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040097425-A1 | Peptide compounds | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| WO-2004009589-A1 | NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-01-29 | — | — | WO | disclosed |
| US-20030191316-A1 | Ester derivatives | MSD K.K. (JP) | 2003-10-09 | — | — | US | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136595-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, ERBB4 | RIPK1 1370/4885LMNA 4363/4885DPP4 3555/4885 |
| US-11802128-B2 | Azetidine and pyrrolidine PARP1 inhibitors and uses thereof | PARP1, PARP11, PARP12 | RIPK1 745/4885LMNA 790/4885DPP4 3115/4885 |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | RIPK1 3244/4885LMNA 4805/4885DPP4 771/4885 |
| US-20230203033-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | RIPK1 489/4885LMNA 1210/4885DPP4 2389/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | RIPK1 62/4885LMNA 1656/4885DPP4 308/4885 |
| US-20040097425-A1 | Peptide compounds | VIP, NOS1, NOS3 | RIPK1 4296/4885LMNA 4514/4885DPP4 147/4885 |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | RIPK1 2087/4885LMNA 3604/4885DPP4 2975/4885 |
| US-20030191316-A1 | Ester derivatives | CHRM3, CHRM2, CHRM1 | RIPK1 3797/4885LMNA 2377/4885DPP4 2586/4885 |
| US-20060167016-A1 | 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES | PDE7A, P2RY2, CGAS | RIPK1 3408/4885LMNA 3976/4885DPP4 710/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | RIPK1 748/4885LMNA 2412/4885DPP4 3146/4885 |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | RIPK1 2135/4885LMNA 1476/4885DPP4 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.